New hope for halting devastating neurological attacks
NCT ID NCT07410039
Summary
This study aims to see if adding the drug eculizumab to standard steroid treatment is better at controlling severe attacks of neuromyelitis optica spectrum disorder (NMOSD), a rare autoimmune disease that attacks the nerves. It will involve 200 Chinese adults who are having a new or worsening attack affecting their vision or spinal cord. Researchers will compare three treatment groups to find which approach best improves disability and quality of life with the fewest side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROMYELITIS OPTICA SPECTRUM DISORDER ATTACK are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
the First Medical Center of Chinese PLA General Hospital
RECRUITINGBeijing, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact
Conditions
Explore the condition pages connected to this study.